Identifying Biomarkers for IBD Diagnosis and Management

Webinar

On-Demand

Want to share this FREE webinar with a colleague?

Fill out the form below and we'll send your colleague an invitation to the "Identifying Biomarkers for IBD Diagnosis and Management" event.

Driving biomarker discovery is key as proteomics emerges as the next frontier in precision medicine.

In this webinar, you’ll hear how proteomics technology can enhance the identification of biomarkers for the accurate diagnosis of Crohn’s disease and ulcerative colitis, as well as the identification of biomarkers that predict response to TNF inhibitors and other biologics in patients with IBD.

This webinar will explore how reliable, non-invasive proteomic biomarkers are pivotal for personalized treatment and increasing our knowledge of biological pathways involved in disease. Our expert speaker will also present an assay platform that can measure 11,000 biologically relevant proteins in the search for biomarkers.

Attend this webinar to:

Explore the role of biomarkers in tailoring medical care and enhancing precision in pediatric IBD treatment
Uncover serum proteins intricately linked to TNF inhibitor response, gaining insights for improved therapeutic decision-making in IBD
Discover how the SomaScan® 11K Assay transforms non-invasive biomarker discovery, revolutionizing differential pediatric IBD diagnosis.

Speaker

Dr. Towia A. Libermann

Associate Professor of Medicine, Beth Israel Deaconess Medical Center

Harvard Medical School

Towia A. Libermann, Ph.D. is an Associate Professor of Medicine in the Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Libermann is also the Director of the Beth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Center and of the Dana Farmer/Harvard Cancer Center Cancer Proteomics Core. Dr. Libermann is an internationally recognized translational investigator with a strong track record in precision medicine, biomarker discovery and translational studies of immunological diseases and cancer. Dr. Libermann’s lab is focused on applying multi-omics approaches to identify proteins or genes that may be exploited as biomarkers or targets for therapeutic intervention, starting with his seminal discovery of EGF receptor gene amplifications in glioblastomas. Dr. Libermann has been at the forefront of the next generation of proteomics and plays a central role in driving biomarker discovery to the next level. Libermann’s group uses the aptamer-based SomaScan proteomics platform, a modified aptamer-based high multiplex immunoassay platform, to discover and validate diagnostic, predictive, and prognostic biomarkers for various diseases using liquid biopsies such as extracellular vesicles and body fluids. Using the latest in machine learning, Libermann’s group has developed predictor models for applications in early detection, disease diagnosis, prediction of therapeutic response, monitoring of disease progression, and outcome prediction. Dr. Libermann received his PhD in Immunology in 1986 from the Weizmann Institute of Science and Technology, Rehovot and did a postdoctoral fellowship at the Whitehead Institute, Cambridge.

Learn about our editorial policies

Associate Professor of Medicine, Beth Israel Deaconess Medical Center

Harvard Medical School

Brought to you by

Have a question about our online events and webinars? Get in touch here.

Now Available on Demand!

Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.

Want to invite a colleague?

Click the button below to begin inviting a colleague to this Webinar

Drug Discovery

Drug Discovery

Identifying Biomarkers for IBD Diagnosis and Management